12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-TTR01: Preliminary Phase I data

Preliminary data from a placebo-controlled, dose-escalation, European Phase I trial in 31 evaluable patients with TTR-mediated amyloidosis showed that single doses of 0.01-1 mg/kg IV ALN-TTR01 were well tolerated. Additionally,...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >